Ticker
AKRO

Price
49.50
Stock movement up
+0.79 (1.62%)
Company name
Akero Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
2.31B
Ent value
1.98B
Price/Sales
-
Price/Book
6.74
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
199.82%
3 year return
25.74%
5 year return
-
10 year return
-
Last updated: 2023-01-31

DIVIDENDS

AKRO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book6.74
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count46.76M
EPS (TTM)-3.14
FCF per share (TTM)-2.42

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)57.30M
Operating income (TTM)-122.17M
Net income (TTM)-121.40M
EPS (TTM)-3.14
EPS (1y forward)-3.50

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash374.00M
Net receivables0.00
Total current assets377.95M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets379.41M
Accounts payable6.01M
Short/Current long term debt10.89M
Total current liabilities25.24M
Total liabilities35.90M
Shareholder's equity343.51M
Net tangible assets343.51M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-93.70M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-93.70M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-35.34%
Return on Assets-32.00%
Return on Invested Capital-34.37%
Cash Return on Invested Capital-26.53%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open48.85
Daily high49.66
Daily low48.41
Daily Volume434K
All-time high54.80
1y analyst estimate52.00
Beta-0.91
EPS (TTM)-3.14
Dividend per share-
Ex-div date-
Next earnings date23 Feb 2023

Downside potential

Loading...
Downside potential data
AKROS&P500
Current price drop from All-time high-9.67%-14.91%
Highest price drop-79.96%-56.47%
Date of highest drop1 Jun 20229 Mar 2009
Avg drop from high-33.12%-11.49%
Avg time to new high29 days13 days
Max time to new high571 days1805 days
COMPANY DETAILS
AKRO (Akero Therapeutics Inc) company logo
Marketcap
2.31B
Marketcap category
Mid-cap
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Employees
34
Investor relations
-
SEC filings
CEO
Andrew Cheng
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
January 10, 2023
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
January 4, 2023
Akero Therapeutics Inc (NASDAQ: AKRO) completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH) in patients with compensated cirrh...
December 22, 2022
Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023 Results of the cohort D expansion to evaluate EFX in combination with GLP-1 therapy...
December 21, 2022
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
December 20, 2022
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeksSOUTH SAN...
December 8, 2022
If you want to know who really controls Akero Therapeutics, Inc. ( NASDAQ:AKRO ), then you'll have to look at the...
November 13, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...
November 10, 2022
Here is how Akero Therapeutics, Inc. (AKRO) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
November 7, 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD categorySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics,...
November 7, 2022
Next page